Role of Interleukin-5 in the Pathophysiology and Treatment of Eosinophilic Asthma

Nightingale Syabbalo

Role of Interleukin-5 in the Pathophysiology and Treatment of Eosinophilic Asthma

Nightingale Syabbalo *

Contact

Role of Interleukin-5 in the Pathophysiology and Treatment of Eosinophilic Asthma

Article Fingerprint

ReserarchID

MRV3178

Role of Interleukin-5 in the Pathophysiology and Treatment of Eosinophilic Asthma Banner

Key Research Insights

Synthesized scholarly intelligence & interactive research assistant

Abstract

Asthma is a heterogeneous chronic airway disease with several distinct phenotypes characterized by different immune pathological pathways, clinical features, disease severity, physiology, and response to treatment. Approximately 50% of patients with stable chronic asthma have the eosinophilic phenotype, whereas the remainder have the non-eosinophilic asthma. Eosinophilic asthma is the most common phenotype in children with acute severe asthma, but neutrophilic asthma is the most common in adult patients presenting with acute severe asthma. T helper 2 (Th2) cytokines, such as interleukin-5 (IL-5), IL-4, IL-13, IL-25, IL-33, and thymic stromal lymphopoitein (TSLP), play a very important role in the pathophysiology of eosinophilic asthma. Interlukin-5 is the pivotal cytokine responsible for the proliferation, differentiation, activation, and survival of eosinophils; and promotion of eosinophil migration and airway eosinophilia. Activated eosinophils secrete granular cytotoxic cationic proteins, such as major basic protein, eosinophil cationic protein, eosinophil-derived neurotoxin, eosinohil-derived peroxide, and reactive oxygen species.

References

129 Cites in Article

Reference Format

(2020). Global Strategy for Asthma management and Prevention -updated.
N Pearce,N Ait-Khaled,R Beasley,J Mallol,U Keil,E Mitchell,C Robertson (2007). Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC).
J Minov (2014). Asthma-COPD Overlap Syndrome Developed in Herbal Tea Processor with Sensitizer-Induced Occupational Asthma – A Case Report.
M Asher,Stephen Montefort,Bengt Björkstén,Christopher Lai,David Strachan,Stephan Weiland,Hywel Williams (2006). Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys.
N Behbehani,A Abul,N Syabbalo,A Azeem (2000). Prevalence of asthma, allergic rhinitis, and eczema in 13-to-14 year-old children in Kuwait: an ISAAC study.
S Wenzel,L Schwartz,E Langmack,J Halliday,J Trudeau,R Gibbs (1999). Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics.
Jodie Simpson,Rodney Scott,Michael Boyle,Peter Gibson (2006). Inflammatory subtypes in asthma: Assessment and identification using induced sputum.
G Anderson (2008). Endotypying asthma: new insights into key pathogenic mechanism in a heterogenous disease.
Sally Wenzel (2012). Asthma phenotypes: the evolution from clinical to molecular approaches.
Ian Pavord,Richard Beasley,Alvar Agusti,Gary Anderson,Elisabeth Bel,Guy Brusselle,Paul Cullinan,Adnan Custovic,Francine Ducharme,John Fahy,Urs Frey,Peter Gibson,Liam Heaney,Patrick Holt,Marc Humbert,Clare Lloyd,Guy Marks,Fernando Martinez,Peter Sly,Erika Von Mutius,Sally Wenzel,Heather Zar,Andy Bush (2018). After asthma: redefining airways diseases.
Lucy Pembrey,Mauricio Barreto,Jeroen Douwes,Philip Cooper,John Henderson,Harriet Mpairwe,Cristina Ardura-Garcia,Martha Chico,Collin Brooks,Alvaro Cruz,Alison Elliott,Camila Figueiredo,Sinéad Langan,Beatrice Nassanga,Susan Ring,Laura Rodrigues,Neil Pearce (2018). Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration.
Matthew Loza,Ratko Djukanovic,Kian Chung,Daniel Horowitz,Keying Ma,Patrick Branigan,Elliot Barnathan,Vedrana Susulic,Philip Silkoff,Peter Sterk,Frédéric Baribaud (2016). Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study.
Diane Lefaudeux,Bertrand De Meulder,Matthew Loza,Nancy Peffer,Anthony Rowe,Frédéric Baribaud,Aruna Bansal,Rene Lutter,Ana Sousa,Julie Corfield,Ioannis Pandis,Per Bakke,Massimo Caruso,Pascal Chanez,Sven-Erik Dahlén,Louise Fleming,Stephen Fowler,Ildiko Horvath,Norbert Krug,Paolo Montuschi,Marek Sanak,Thomas Sandstrom,Dominic Shaw,Florian Singer,Peter Sterk,Graham Roberts,Ian Adcock,Ratko Djukanovic,Charles Auffray,Kian Chung,Nora Adriaens,Hassan Ahmed,Antonios Aliprantis,Kjell Alving,Philipp Badorek,David Balgoma,Clair Barber,An Bautmans,Annelie Behndig,Elisabeth Bel,Jorge Beleta,Ann Berglind,Alix Berton,Jeanette Bigler,Hans Bisgaard,Grazyna Bochenek,Michael Boedigheimer,Klaus Bøonnelykke,Joost Brandsma,Armin Braun,Paul Brinkman,Dominic Burg,Davide Campagna,Leon Carayannopoulos,João Carvalho Da Purfição Rocha,Amphun Chaiboonchoe,Romanas Chaleckis,Courtney Coleman,Chris Compton,Arnaldo D'amico,Barbro Dahlén,Jorge De Alba,Pim De Boer,Inge De Lepeleire,Tamara Dekker,Ingrid Delin,Patrick Dennison,Annemiek Dijkhuis,Aleksandra Draper,Jessica Edwards,Rosalia Emma,Magnus Ericsson,Veit Erpenbeck,Damijan Erzen,Cornelia Faulenbach,Klaus Fichtner,Neil Fitch,Breda Flood,Urs Frey,Martina Gahlemann,Gabriella Galffy,Hector Gallart,Trevor Garret,Thomas Geiser,Jilaiha Gent,Maria Gerhardsson De Verdier,David Gibeon,Cristina Gomez,Kerry Gove,Neil Gozzard,Yi-Ke Guo,Simone Hashimoto,John Haughney,Gunilla Hedlin,Pieter-Paul Hekking,Elisabeth Henriksson,Lorraine Hewitt,Tim Higgenbottam,Uruj Hoda,Jans Hohlfeld,Cecile Holweg,Peter Howarth,Richard Hu,Sile Hu,Xugang Hu,Val Hudson,Anna James,Juliette Kamphuis,Erika Kennington,Dyson Kerry,Matthias Klüglich,Hugo Knobel,Richard Knowles,Alan Knox,Johan Kolmert,Jon Konradsen,Maxim Kots,Linn Krueger,Scott Kuo,Maciej Kupczyk,Bart Lambrecht,Ann-Sofie Lantz,Lars Larsson,Nikos Lazarinis,Saeeda Lone-Satif,Lisa Marouzet,Jane Martin,Sarah Masefield,Caroline Mathon,John Matthews,Alexander Mazein,Sally Meah,Andrea Maiser,Andrew Menzies-Gow,Leanne Metcalf,Roelinde Middelveld,Maria Mikus,Montse Miralpeix,Philips Monk,Nadia Mores,Clare Murray,Jacek Musial,David Myles,Shama Naz,Katja Nething,Ben Nicholas,Ulf Nihlen,Peter Nilsson,Björn Nordlund,Jörgen Östling,Antonio Pacino,Laurie Pahus,Susanna Palkonnen,Stelios Pavlidis,Giorgio Pennazza,Anne Petrén,Sandy Pink,Anthony Postle,Pippa Powel,Malayka Rahman-Amin,Navin Rao,Lara Ravanetti,Emma Ray,Stacey Reinke,Leanne Reynolds,Kathrin Riemann,John Riley,Martine Robberechts,Amanda Roberts,Christos Rossios,Kirsty Russell,Michael Rutgers,Giuseppe Santini,Marco Sentoninco,Corinna Schoelch,James Schofield,Wolfgang Seibold,Ralf Sigmund,Marcus Sjödin,Paul Skipp,Barbara Smids,Caroline Smith,Jessica Smith,Katherine Smith,Päivi Söderman,Adesimbo Sogbesan,Doroteya Staykova,Karin Strandberg,Kai Sun,David Supple,Marton Szentkereszty,Lilla Tamasi,Kamran Tariq,John-Olof Thörngren,Bob Thornton,Jonathan Thorsen,Salvatore Valente,Wim Van Aalderenm,Marianne Van De Pol,Kees Van Drunen,Marleen Van Geest,Jenny Versnel,Jorgen Vestbo,Anton Vink,Nadja Vissing,Christophe Von Garnier,Arianne Wagerner,Scott Wagers,Frans Wald,Samantha Walker,Jonathan Ward,Zsoka Weiszhart,Kristiane Wetzel,Craig Wheelock,Coen Wiegman,Siân Williams,Susan Wilson,Ashley Woosdcock,Xian Yang,Elizabeth Yeyashingham,Wen Yu,Wilhelm Zetterquist,Koos Zwinderman (2016). U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics.
Pranab Haldar,Ian Pavord (2007). Noneosinophilic asthma: A distinct clinical and pathologic phenotype.
F Aleman,H Lim,P Nair (2016). Eosinophilic endotype of asthma.
Steven Taylor,Lex Leong,Jocelyn Choo,Steve Wesselingh,Ian Yang,John Upham,Paul Reynolds,Sandra Hodge,Alan James,Christine Jenkins,Matthew Peters,Melissa Baraket,Guy Marks,Peter Gibson,Jodie Simpson,Geraint Rogers (2018). Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology.
P Ntontsi,S Loukides,P Bakakos,K Kostikas,G Papatheodorou,E Papathanassiou,A Papaporfyriou,E Konstantellou (2016). Clinical, functional and inflammatory characteristics in patients with paucigranulocytic asthma.
David Birnkrant (2007). Guidelines for the Diagnosis and Management of Asthma. National Asthma Education and Prevention Program Expert Panel, NIH, February, 1997.
F Holguin,J Cardet,K Chung,S Diver,D Ferriera,A Fitzpatrick,M Gaga,L Kellermeyer (2020). Management of severe asthma: A European Respiratory Society/American Thoracic Society guidelines.
M Peters,S Kerr,E Duncan,P Woodruff,M Fajt,B Levy,Isreal Phillips,B National Lung and Blood Institute Severe Asthma Research Program-3 (2018) Refractory airway type-2 inflammation in a large subgroup of asthmatics treated with inhaled corticosteroids.
G Futura,F Atkins,N Lee (2014). Changing roles of eosinophils in health and disease.
A Vaglio,C Buzio,J Zwerina (2013). Eosinophilic granulomatosis with polyangiitis (<scp>C</scp>hurg–<scp>S</scp>trauss): state of the art.
P Ehrlich (1879). Beiträge zur Kenntniss der granulirten Bindegewebszellen und der eosinophilen Leukocythen.
A Fraenkel (1900). Zur Pathologie des Bronchialasthma.
J Houston,S De Navasquez,J Trounce (1953). A Clinical and Pathological Study of Fatal Cases of Status Asthmaticus.
Jean Bousquet,Pascal Chanez,Jean Lacoste,Gilbert Barnéon,Nouchine Ghavanian,Ingrid Enander,Per Venge,Staffan Ahlstedt,Joelle Simony-Lafontaine,Philippe Godard,François-Bernard Michel (1990). Eosinophilic Inflammation in Asthma.
Helene Rosenberg,Simon Phipps,Paul Foster (2007). Eosinophil trafficking in allergy and asthma.
C Blanchard,M Rothenberg (2009). Biology of eosinophils.
C Mcbrien,A Menzies-Gow (2017). The biology of eosinophils and their role in asthma.
J Du,M Stankiewicz,Y Liu,Q Xi,J Schmidt,J Lekstrom-Hime (2002). Novel combinatorial interactions of GATA-1, PU.1, and C/EBP episolon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein.
Bart Lambrecht,Hamida Hammad (2015). The immunology of asthma.
James Pease (2006). Asthma, Allergy and Chemokines.
D Griffithsjohnson,P Collins,A Rossi,P Jose,T Williams (1993). The Chemokine, Eotaxin, Activates Guinea-Pig Eosinophils in Vitro and Causes Their Accumulation into the Lung in Vivo.
Gui-Quan Jia,Jose-Angel Gonzalo,Andres Hidalgo,Denisa Wagner,Myron Cybulsky,Jose Gutierrez-Ramos (1999). Selective eosinophil transendothelial migration triggered by eotaxin via modulation of Mac-1/ICAM-1 and VLA-4/VCAM-1 interactions.
Sun Ying,Qiu Meng,Kyriaki Zeibecoglou,Douglas Robinson,Alison Macfarlane,Marc Humbert,A Kay (1999). Eosinophil Chemotactic Chemokines (Eotaxin, Eotaxin-2, RANTES, Monocyte Chemoattractant Protein-3 (MCP-3), and MCP-4), and C-C Chemokine Receptor 3 Expression in Bronchial Biopsies from Atopic and Nonatopic (Intrinsic) Asthmatics.
Mats Johansson,Elizabeth Kelly,William Busse,Nizar Jarjour,Deane Mosher (2008). Up-Regulation and Activation of Eosinophil Integrins in Blood and Airway after Segmental Lung Antigen Challenge.
Amy Klion,Thomas Nutman (2004). The role of eosinophils in host defense against helminth parasites.
A Kay (2015). The early history of the eosinophil.
E Jacobson,R Helmer,J Lee,N Lee (2012). The expanding role(s) of eosinophils in health and disease.
Lisa Spencer,Craig Szela,Sandra Perez,Casey Kirchhoffer,Josiane Neves,Amy Radke,Peter Weller (2009). Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially.
Christianne Bandeira-Melo,Patricia Bozza,Peter Weller (2002). The cellular biology of eosinophil eicosanoid formation and function.
Rakesh Singh,Ruchi Tandon,Sunanda Dastidar,Abhijit Ray (2013). A review on leukotrienes and their receptors with reference to asthma.
T Horiuchi,P Weller (1997). Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colonystimulating factor and interleukin-5.
Gerald Gleich (2000). Mechanisms of eosinophil-associated inflammation.
Simon Hogan,Helene Rosenberg,Redwan Moqbel,Simon Phipps,Paul Foster,Paige Lacy,A Kay,Marc Rothenberg (2008). Eosinophils: Biological Properties and Role in Health and Disease.
Lívia Carmo,Kennedy Bonjour,Shigeharu Ueki,Josiane Neves,Linying Liu,Lisa Spencer,Ann Dvorak,Peter Weller,Rossana Melo (2016). CD63 is tightly associated with intracellular, secretory events chaperoning piecemeal degranulation and compound exocytosis in human eosinophils.
Gerald Gleich (1993). Eosinophil granule proteins and bronchial asthma.
A Trulson,J Byström,A Engström,R Larsson,P Venge (2007). The functional heterogeneity of eosinophilic cationic protein determined by a gene polymorphism and post-transitional modifications.
Null- Young,Christer Peterson,Per Venge,Zanvil Cohn (1986). Mechanism of membrane damage mediated by human eosinophil cationic protein.
G Gleich,N Flavahan,T Fujisawa,P Vanhoutte (1988). The eosinophil as a mediator of damage to respiratory epithelium: A model for bronchial hyperreactivity.
H Rosenberg (2008). Eosinophil-Derived Neurotoxin / RNase 2: Connecting the Past, the Present and the Future.
Ross Morgan,Richard Costello,Niamh Durcan,Paul Kingham,Gerald Gleich,W Mclean,Marie-Therese Walsh (2005). Diverse Effects of Eosinophil Cationic Granule Proteins on IMR-32 Nerve Cell Signaling and Survival.
A Kay (1983). Mediators of hypersensitivity and inflammatory cells in the pathogenesis of bronchial asthma.
Marc Peters-Golden,William Henderson (2007). Leukotrienes.
Bruce Bochner,Gerald Gleich (2010). What targeting eosinophils has taught us about their role in diseases.
L Spencer,C Szela,S Perez (2009). Human eosinophils constitutively express multiple Th1, and Th2 and immunoregulatory cytokines that are secreted rapidly and differentially.
Sheharyar Durrani,Ravi Viswanathan,William Busse (2011). What effect does asthma treatment have on airway remodeling? Current perspectives.
Peter Barnes (2008). The cytokine network in asthma and chronic obstructive pulmonary disease.
Bita Shakoory,S Fitzgerald,Steven Lee,David Chi,Guha Krishnaswamy (2004). The Role of Human Mast Cell-Derived Cytokines in Eosinophil Biology.
Maria Galdiero,Gilda Varricchi,Mansour Seaf,Giancarlo Marone,Francesca Levi-Schaffer,Gianni Marone (2017). Bidirectional Mast Cell–Eosinophil Interactions in Inflammatory Disorders and Cancer.
J Kips (2001). Cytokines in asthma.
John Steinke,Larry Borish (2001). Th2 cytokines and asthma — Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists.
Jesse Nussbaum,Steven Van Dyken,Jakob Von Moltke,Laurence Cheng,Alexander Mohapatra,Ari Molofsky,Emily Thornton,Matthew Krummel,Ajay Chawla,Hong-Erh Liang,Richard Locksley (2013). Type 2 innate lymphoid cells control eosinophil homeostasis.
Hiroki Kabata,Kazuyo Moro,Shigeo Koyasu,Koichiro Asano (2015). Group 2 innate lymphoid cells and asthma.
Julia Wisniewski,Larry Borish (2011). Novel cytokines and cytokine-producing T cells in allergic disorders.
Yael Minai-Fleminger,Moran Elishmereni,Francesca Vita,Maria Rosa Soranzo,David Mankuta,Guliano Zabucchi,Francesca Levi-Schaffer (2010). Ultrastructural evidence for human mast cell-eosinophil interactions in vitro.
Prescott Woodruff,Barmak Modrek,David Choy,Guiquan Jia,Alexander Abbas,Almut Ellwanger,Joseph Arron,Laura Koth,John Fahy (2009). T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma.
Guy Brusselle,Tania Maes,Ken Bracke (2013). Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma.
Jennifer Walker,Jillian Barlow,Andrew Mckenzie (2013). Innate lymphoid cells — how did we miss them?.
Steven Smith,Ruchong Chen,Melanie Kjarsgaard,Chynna Huang,John-Paul Oliveria,Paul O'byrne,Gail Gauvreau,Louis-Philippe Boulet,Catherine Lemiere,James Martin,Parameswaran Nair,Roma Sehmi (2016). Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia.
Tsutomu Yanagibashi,Mitsuo Satoh,Yoshinori Nagai,Masamichi Koike,Kiyoshi Takatsu (2017). Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5.
Bart Lambrecht,Hamida Hammad,John Fahy (2019). The Cytokines of Asthma.
Bart Lambrecht,Hamida Hammad (2015). The immunology of asthma.
M Milburn,A Hassell,M Lambert (1993). A novel dimer configuration revealed by the crystal structure at 2.4 Å resolution of human interleukin-5.
M Mckinnon,M Bank,R Solari,G Robinson (1999). Interleukin-5 and the interleukin receptor: target for drug discovery in asthma.
Andrew Menzies-Gow,Patrick Flood-Page,Roma Sehmi,John Burman,Qutayba Hamid,Douglas Robinson,A Kay,Judah Denburg (2003). Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.
S Greenfender,S Umland,F Cuss,R Chapman,R Egan (2001). Th2 cytokines and asthma -The role of interleukin-5 in allergic eosinophilic disease.
E Clutterbuck,E Hirst,C Sanderson (1989). Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF.
T Kouro,K Takatsu (2009). IL-5- and eosinophil-mediated inflammation: from discovery to therapy.
Tetsuya Adachi,Rafeul Alam (1998). The mechanism of IL-5 signal transduction.
N Molfino,D Gossage,R Kolbeck,J Parker,G Geba (2012). Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor.
R Alam,Pazdrak,S Stafford,P Forsythe (1995). The interleukin-5/receptor interaction activates Lyn and JAK2 tyrosine kinase and signals via Ras-Raf-1-MAP kinase and the JAK-STAT pathway in eosinophils.
Konrad Pazdrak,Barbara Olszewska-Pazdrak,Susan Stafford,Roberto Garofalo,Rafeul Alam (1998). Lyn, Jak2, and Raf-1 Kinases Are Critical for the Antiapoptotic Effect of Interleukin 5, whereas only Raf-1 Kinase Is Essential for Eosinophil Activation and Degranulation.
Masaaki Sano,Alan Leff,Shigeharu Myou,Evan Boetticher,Angelo Meliton,Jonathan Learoyd,Anissa Lambertino,Nilda Munoz,Xiangdong Zhu (2005). Regulation of Interleukin-5–Induced β <sub>2</sub> -Integrin Adhesion of Human Eosinophils by Phosphoinositide 3-Kinase.
Tetsuya Adachi,Barun Choudhury,Susan Stafford,Sanjiv Sur,Rafeul Alam (2000). The Differential Role of Extracellular Signal-Regulated Kinases and p38 Mitogen-Activated Protein Kinase in Eosinophil Functions.
Wai Ip,Chun Wong,Cheng Wang,Ya Tian,Christopher Lam (2005). Interleukin-3, -5, and Granulocyte Macrophage Colony-Stimulating Factor Induce Adhesion and Chemotaxis of Human Eosinophils via p38 Mitogen-Activated Protein Kinase and Nuclear Factor κB.
Gilda Varricchi,Giorgio Canonica (2016). The role of interleukin 5 in asthma.
Gilda Varricchi,Diego Bagnasco,Francesco Borriello,Enrico Heffler,Giorgio Canonica (2016). Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders.
V Agumadu,K Ramphul,S Mejias,R Sonaye,S Sombans,P Lohana (2018). A review of three antiinterleukin-5 monoclonal antibody therapies for severe asthma.
Zia-Amirhosseini P Minthorn,E Benincosa,L Hart,T Hottenstein,C Tobias,L (1999). Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.
A Lopez,C Sanderson,J Gamble,H Campbell,I Young,M Vadas (1988). Recombinant human interleukin 5 is a selective activator of human eosinophil function..
Tsukasa Ohnishi,Sanjiv Sur,Donald Collins,James Fish,Gerald Gleich,Stephen Peters (1993). Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge.
G Gnanakumaran,K Babu (2003). Technology evaluation: mepolizumab, GlaxoSmithKline.
Diego Bagnasco,Marco Caminati,Matteo Ferrando,Teresita Aloè,Elisa Testino,Giorgio Canonica,Giovanni Passalacqua (2018). Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma.
M Leckie,A Ten Brinke,J Khan,Z Diamant,O' Connor,B Walls,C (2000). Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper responsiveness, and the late asthmatic response.
I Pavord,S Korns,P Howarth,E Bleecker,L Buhl,O Keene (2012). Mepolizumab for severe asthma (DREAM): a multicenter, double-blind, placebocontrolled trial.
Hector Ortega,Mark Liu,Ian Pavord,Guy Brusselle,J Fitzgerald,Alfredo Chetta,Marc Humbert,Lynn Katz,Oliver Keene,Steven Yancey,Pascal Chanez (2014). Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma.
Elisabeth Bel,Sally Wenzel,Philip Thompson,Charlene Prazma,Oliver Keene,Steven Yancey,Hector Ortega,Ian Pavord (2014). Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma.
G Chupp,E Bradford,F Albers,D Bratton,J Wang-Jairaj,L Nelsen (2015). Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomized, double-blind, placebo-controlled, parallel-group, multi-center, phase 3b trial.
J Zhang,R Kuvelkar,N Murgolo,S Taremi,C Chou,P Wang (1999). Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5.
J Kips,O' Connor,B Langley,S Woodcock,A Kerstjens,H Postma,D (2003). Effect of SCH55700, a humanized antihuman anterleukin-5 antibody, in severe persistent asthma. A pilot study.
M Castro,S Mathur,F Hargreave,L Boulet,F Xie,J Young (2011). Reslizumab for poorly controlled asthma: a randomized, placebo-controlled study.
M Castro,J Zangrilli,M Wechsler,E Bateman,G Brusselle,P Bardin (2015). Reslizumab for inadequately controlled asthma with elevated eosinophil count: results from two multicentre, parallel, double-blind, randomised, placebocontrolled, phase 3 trials.
L Bjermer,C Lemiere,J Maspero,S Weiss,J Zangrilli,M Germinaro (2016). Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study.
G Brusselle,M Germinaro,S Weiss,J Zangrilli,T Pasut,G Scibek,J Chaiken,I (2004). Kinetic interaction analysis of human interleukin 5 receptor α mutants reveals a unique binding topology and charge distribution for cytokine recognition.
R Kolbeck,A Kozhich,M Koike,L Peng,C Andersson,M Damschroder (2010). Medi-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell mediated cytotoxicity function.
C Pelaia,G Paoletti,F Puggioni,F Racca,G Pelaia,G Canonica,E Heffler (2019). Interleukin-5 in the pathophysiology of severe asthma.
R Shields,J Lai,R Keck,O' Connell,L Hong,K Meng,Y (2002). Lack of fucose on human IgG1 Nlinked oligosaccharide improves binding to Fcgamma RIII and antibody-dependent cellular toxicity.
A Ghazi,A Trikha,W Calhoun (2012). Benralizumab -a humanized mAb to IL-5 with enhanced antibodydependent cell-mediated cytotoxicity -a novel approach for the treatment of asthma.
D Bagnasco,M Ferrando,G Varricchi,F Puggioni,G Passalacqua,G Canonica (2017). Anti-interleukin 5 (IL-5) and IL-5Ra: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma.
L Tan,J Bratt,D Godor,S Louie,N Kenyon (2016). Benralizumab: a unique IL-5 inhibitor for severe asthma.
Mario Castro,Sally Wenzel,Eugene Bleecker,Emilio Pizzichini,Piotr Kuna,William Busse,David Gossage,Christine Ward,Yanping Wu,Bing Wang,Deepak Khatry,René Van Der Merwe,Roland Kolbeck,Nestor Molfino,Donald Raible (2014). Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
M Laviolette,D Gossage,G Gauvreau,R Leigh,R Olivenstein,R Katail (2013). Effect of benralizumab on airway eosinophil in asthmatic patients with sputum eosinophilia.
E Bleecker,J Fitgerald,P Chanez,A Papi,S Weinstein,P Baker (2016). Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dose inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomized multicentre, placebo controlled phase 3 trial.
J Fitzgerald,E Bleecker,P Nair,S Korn,S Ohta,M Lommatzsch (2016). Benralizumab, an antiinterleukin-5 receptor monoclonal antibody, as addon treatment for patients with severe asthma, uncontrolled eosinophilic asthma (CALIMA): a randomized, double-blind,placebo-controlled phase 3 trial.
J Fitzgerald,Eugene Bleecker,Andrew Menzies-Gow,James Zangrilli,Ian Hirsch,Paul Metcalfe,Paul Newbold,Mitchell Goldman (2018). Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
P Nair,S Wenzel,K Rabe,A Bourdin,N Lugogo,P Kuna (2017). Oral glucocorticoid-sparing effect of benralizumab in severe asthma.
E Busse,R Bleecker,J Fitzgerald,G Ferguson,P Barker,S Sproule (2019). Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.
C Pelaia,M Busceti,A Vatrella,G Rago,C Crimi,R Terracciano (2019). Real-life rapidity of benralizumab effects in patients with severe allergic asthma: assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
F Schleich,Sophie Renaud,L ; Wan,X Woodruff,P (2016). Biomarkers in the management of difficult asthma.
Steven Yancey,Oliver Keene,Frank Albers,Hector Ortega,Stewart Bates,Eugene Bleecker,Ian Pavord (1003). Biomarkers for severe eosinophilic asthma.
A Riccio,R Dal Negro,C Micheletto,L De Ferrari,C Folli,A Chiappori,G Canonica (2012). Omalizumab Modulates Bronchial Reticular Basement Membrane Thickness and Eosinophil Infiltration in Severe Persistent Allergic Asthma Patients.
Simon Phipps,Patrick Flood-Page,Andrew Menzies-Gow,Yee Ong,A Kay (2004). Intravenous Anti-IL-5 Monoclonal Antibody Reduces Eosinophils and Tenascin Deposition in Allergen-Challenged Human Atopic Skin.
F Holguin,J Cardet,K Chung,S Diver,D Ferriera,A Fitzpatrick,M Gaga,L Kellermeyer (2020). Management of severe asthma: A European Respiratory Society/American Thoracic Society guidelines.
M Bogart,A Roberts,S Wheeler Cost-effectiveness of refractory asthma treatment strategies: a decision tree analysis.
R Niven,M Simmonds,M Cangelosi,D Tilden,S Cottrell,N Shargill (2017). Indirect comparison of bronchial thermoplasty versus omalizumab for uncontrolled asthma.
P Bonta,P Chanez,J Annema,P Shah,Niven (2018). Bronchial thermoplasty in severe asthma: best practice recommendations from an expert panel.
Jns Hooghe,Ten Hacken,Nht Weersink,Ejm Sterk,P Annema,J Bonta,Pi ; Thomson,N (2018). Bronchial thermoplasty as a treatment for severe asthma: controversies, progress and uncertainties.
(null). Fig. 1. Molecular mechanisms of the pathogenesis of bronchial asthma in a group of patients with high Th2 level. Notes: IL — interleukin; Th2 cells — type 2 T helper cells; TSLP — thymic stromal lymphopoietin; DC — dendritic cells; IgE — immunoglobulin E; PGD2 — prostaglandins D2; CysLT — cysteinyl leukotrienes; ECP — eosinophilic cationic proteins; EDN — eosinophil-derived neurotoxin; EPx — eosinophil peroxidase; MBP — major alkaline protein..

Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Nightingale Syabbalo. 2020. "Role of Interleukin-5 in the Pathophysiology and Treatment of Eosinophilic Asthma". Global Journal of Medical Research - F: Diseases GJMR-F Volume 20 (GJMR Volume 20 Issue F9).

More Citation Formats

Select Citation Style:

Download Citation

GJMR Volume 20 Issue F9

Explore Journals Explore Volume Read This Issue

Journal Specifications

Crossref Journal DOI 10.17406/gjmr

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords

Not Found

Classification

GJMR-F Classification NLMC Code: WF 140

Submission ReceivedDecember 13, 2019
Peer Review Double Blind
Handling Editor
Accepted January 4, 2020
Published January 15, 2020

Version of record

v1.2

Issue date

October 5, 2020

Language

English

Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D

Article Matrices

Total Views: 774

Total Downloads: 36

All Trends